Skip to contentE
Endonovo Therapeutics, Inc.
E
ENDVEndonovo Therapeutics, Inc. Q1 2023 · 10-Q
Revenue$87.54K$87.54K+3,736.1% vs Q1 2022 Net Income$7.23M$7.23MN/M vs Q1 2022 EPS Diluted$0.00$0.00N/M vs Q1 2022 Gross Profit$83,544+5,228.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR
Operating Cash Flow-$173,156N/M Margins · derivedGross margin95.4%+26.7 pt vs Q1 2022
Operating margin-604.6%+20682.1 pt vs Q1 2022
Net margin8259.7%+114009.4 pt vs Q1 2022
ended Mar 31, 2023 · filed May 22, 2023 · 52 d after period end